StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'
October 4, 2016 9:13 AM
Baird affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $102 following a new licensing agreement with ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Oppenheimer Keeps Summit Therapeutics (SMMT) at 'Outperform' Amid New DMD Deal (SRPT)
October 4, 2016 9:31 AM
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
October 4, 2016 9:01 AM
Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal
October 4, 2016 8:56 AM
Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer
October 4, 2016 8:44 AM
Threat of 'hard Brexit' pulls down Wall Street
October 4, 2016 7:44 AM
Form 8-K Sarepta Therapeutics, For: Oct 03
October 4, 2016 7:05 AM
Sarepta (SRPT), Summit Therapeutics (SMMT) Enter Licensing Agreement for Utrophin Modulator Pipeline
October 4, 2016 7:02 AM
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 4, 2016 7:00 AM
